Exelixis

Exelixis, Inc., the US biotechnology company behind cancer therapies such as cabozantinib, is seeing heightened interest in its stock (NASDAQ: EXEL). Investors are tracking the share price, recent quotes and trading history as they weigh the company's outlook in the competitive oncology market. Financial news pages listing the company's performance and updates are being widely consulted.